相关实验视频

Updated: Jul 13, 2025

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

在肝癌中,基于联体受体对的分子模式和预后风险模型的识别

Pengbo Hu¹, Liang Xu¹, Yongqing Liu¹

¹Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Frontiers in immunology

|October 11, 2023

概括

这项研究揭示了肝细胞癌 (肝癌) 的新型受体-连接体模型,该模型可以预测患者的预后和治疗反应. 准SLC1A5显示出抑制肝癌进展的潜力.

科学领域:

在瘤学瘤学.
生物信息学是一种生物信息学.
免疫学免疫学免疫学

背景情况:

肝细胞癌 (HCC) 中的瘤微环境 (TME) 涉及复杂的细胞-细胞通信驱动瘤进展.
单细胞技术可以对瘤内的细胞通信网络进行详细分析.

研究的目的:

建立基于受体-连接体相互作用的肝癌 (LIHC) 的分子类型和风险模型.
研究这些模型与临床特征,预后,突变,TME,免疫透,瘤突变负担 (TMB) 和药物敏感性的关联.
为了验证SLC1A5在HCC进展中的功能作用.

主要方法:

应用生物信息技术对来自LIHC的单细胞和转录基因组测序数据.
使用受体-连接体对构建分子类型和风险模型.
进行了qPCR,CCK8,transwell和细胞殖民地形成试验,以评估SLC1A5的功能.
分析了巨细胞极化和其他TME组件.

主要成果:

确定肝癌组织富含免疫和介质细胞,具有广泛的细胞信号传递.
开发了分子类型和风险模型,证明了临床特征,预后和药物敏感性的显著差异.
在激活的信号通路,免疫细胞透和免疫亚型中观察到显著的差异.
证明使用siRNA击败SLC1A5可以减少HCC细胞的增殖,迁移和入侵.

结论:

开发的受体-连接体 (LR) 模型显示出作为指导临床治疗和预测HCC预后的生物标志物具有前景.
SLC1A5在HCC进展中起着至关重要的作用,并代表着潜在的治疗点.

关键词:

在TME中,它是最重要的.结合体受体的结合体受体肝癌肝癌是一种肝癌.分子模式的分子模式.风险模型的风险模型.

更多相关视频

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Ligand Binding Sites

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...